The management of chronic viral hepatitis: A Canadian consensus conference 2004

Canadian Journal of Infectious Diseases

Volumn 15, Issue 6, 2004, Pages 313-326

  Sherman, Morris ^a,g   Bain, Vincent ^b   Villeneuve, Jean Pierre ^c   Myers, Robert P ^d   Cooper, Curtis ^e   Martin, Steven ^c   Lowe, Catherine ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Adefovir; Chronic viral hepatitis; Interferon; Lamivudine

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; DIDANOSINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ANEMIA; CANADA; CONFERENCE PAPER; CONSENSUS; FATTY LIVER; FEVER; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; LACTIC ACIDOSIS; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; NEUTROPENIA; PANCREATITIS; RASH; SIDE EFFECT; VACCINATION; VIRUS HEPATITIS;

EID: 11244270441     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/326964     Document Type: Conference Paper

References (159)

1. Sherman M. Management of viral hepatitis: Clinical and public health perspectives - a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver. Can J Gastroenterol 1997;11:407-16.
2. Anonymous. Canadian consensus conference on the management of viral hepatitis. Can J Gastroenterol 2000;14(Suppl B):5B-20.
3. Management guidelines for the HCV and HIV co-infected adult: Recommendations of a multidisciplinary expert panel. Can J Infect Dis 2001;12(Suppl A):8A-21A.
4. Kish MA; Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4.
5. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Int Med 2001;135:796-800.
6. Da Villa G, Piccinino F, Scolastico C, Fusco M, Piccinino R, Sepe A. Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): Results of a pilot vaccination project. Res Virol 1998;149:263-70.
7. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
8. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992;89:269-73.
9. Mahoney FJ, Lawrence M, Scott C, Le Q, Lambert S, Farley TA. Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. Pediatrics 1995;96:1113-6.
10. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988;260:2231-5.
11. Zanetti AR, Dentico P, Del Vecchio, et al. Multicentre trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. Final report. J Med Virol 1986;18:327-34.
12. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94-8.
13. Anderson KE, Stevens CE, Tsuei JJ, Lee WC, Sun SC, Beasley P. Hepatitis B antigen in infants born to mothers with chronic hepatitis B antigenemia in Taiwan. Am J Dis Child 1975;129:1389-92.
14. Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health 1998;88:1638-44.
15. Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001;63:220-7.
16. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
17. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-6.
18. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-30.
19. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-53.
20. De Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Int Med 1993;118:191-4.
21. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7.
22. Santagostino E, Colombo M, Rivi M, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003;102:78-82.
23. Trevisani F, De NS, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: Effects on cancer stage and patient survival (Italian experience). Am J Gastro 2002;97:734-44.
24. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002;122:2092-3.
25. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998;93:896-900.
26. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
27. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003;39(Suppl 1):S164-7.
28. Hoofnagle JH. Challenges in therapy of chronic hepatitis B. J Hepatol 2003;39(Suppl 1):S230-5.
29. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
30. Brook MG, Chan G, Yap I, et al. Randomized controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ 1989;299:652-6.
31. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population. Ann Intern Med 1993;119:312-23.
32. Van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
33. Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment. Hepatology 1999;30:238-43.
34. Tine F, Liberati A, Craxi A, et al. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol 1993;18:154-62.
35. Song BC, Suh DJ, Lee HC, et al. Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea? J Clin Gastro 2004;38:124-9.
36. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45.
37. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
38. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
39. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-63.
40. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
41. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
42. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
43. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
44. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial. Gut 2000;46:562-8.
45. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
46. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-44.
47. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after three years of therapy. On behalf of the Asia Hepatitis Lamivudine Study Group. Hepatology 2001;33:1527-32.
48. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22.
49. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (pre-core mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-96.
50. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
51. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon non-responders. J Hepatol 2003;38:818-26.
52. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
53. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
54. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
55. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7.
56. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDA): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 2003;10:298-305.
57. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1,563 Alaska natives chronically infected with hepatitis B virus. Ann Int Med 2001;135:759-68.
58. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10.
59. Lok ASF, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-3.
60. Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: Implications for therapy. J Clin Infect Dis 1997;176:845-50.
61. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origin. J Infect Dis 2002;186:295-301.
62. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial. Gastroenterology 1998;114:988-95.
63. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
64. Van Zonneveld M, van Nunen A, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepatol 2003;10:294-7.
65. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
66. Fontana RJ, Hann HW, Perrillo HP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-27.
67. Ben-Ari Z, Broida E, Kittai Y, et al. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol 2000;95:3579-83.
68. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-9.
69. Nagler A, Ilan Y, Adler R, et al. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant 1995;1:475-8.
70. Remis RS, Dufour A, Alary M, et al. Association of hepatitis B virus infection with other sexually transmitted infections in homosexual men. Omega Study Group. Am J Public Health 2000;90:1570-4.
71. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
72. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997;11:597-606.
73. Scolfaro C, Fiammengo P, Balbo L, et al. Hepatitis B vaccination in HIV-1-infected children: Double efficacy doubling the paediatric dose. AIDS 1996;10:1169-70.
74. Wong EK, Bodsworth NJ, Slade MA, et al. Response to hepatitis B vaccination in a primary care setting: Influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996;7:490-4.
75. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51(RR-8):1-52.
76. Notice to Readers Update: Recommendations to prevent hepatitis B virus transmission - United States. MMWR Recomm Rep 1995;44:574-5.
77. Cooper D, Gore D, Pozniak AL, et al. Tenofovir disoproxil fumarate and lamivudine combination therapy compared to lamivudine alone for HBV in therapy-naïve HIV/HBV co-infected patients: 48 week interim results. In: 10th Conference on Retroviruses and Opportunistic Infections, 2003 February 10-14, 2003, Boston, MA, 2003. (Abst)
78. Da Silva LC, Pinho JR, Sitnik R, Da Fonseca LE, Carrilho FJ. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 2001;36:476-85.
79. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6.
80. Cooper D, Coakley DF, Sayre J, et al. Anti-hepatitis B virus (HBV) activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV co-infected patients. Abstract 6015. In: XIV International AIDS Conference, 2002 July 7-12, 2002, Barcelona, Spain, 2002.
81. Bochet M, Tubiana R, Benhamou Y, et al. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV. Abstract 675-M. In: 9th Conference on Retroviruses and Opportunistic Infections, 2002 February 24-28, 2003, Seattle, WA, 2002.
82. Maio G, d'Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine aminotransferase levels in the general population: A survey in a southern Italian town. J Hepatol 2000;33:116-20.
83. Comandini UV, Tossini G, Longo MA, et al. Sporadic hepatitis C virus infection: A case-control study of transmission routes in a selected hospital sample of the general population in Italy. Scand J Infect Dis 1998;30:11-5.
84. McHutchison JG, Poynard T, Esteban-Mur R, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-93.
85. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
86. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
87. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
88. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
89. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa 2a (40KD) (Pegasys) in combination with ribavirin (RBV): Efficacy and safety results from a phase III randomized double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002;36(Suppl 1):3.
90. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
91. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
92. Shobokshi OA, Serebour FE, Skakni L, et al. Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa 2a (40kD)/RBV J Hepatol 2003;38(Suppl 2):172.
93. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: Management of hepatitis C: 2002. Hepatology 2002;36(Suppl 1):S1-2.
94. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999;31(Suppl 1):3-8.
95. Unitron Peg® (Peginterferon alfa-2b) package insert. Schering Canada. 2003.
96. Pegasys® (Peginterferon alfa-2a) Product Monograph. Hoffman-LaRoche Limited. 2003 〈http://www.rocheusa.com/products/pegasys/pi.pdf〉 (Version current at November 8, 2004).
97. Soza A, Everhart JE, Ghany MO, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
98. McHutchison JO, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
99. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
100. Koliouskas D, Sidiropuolos I, Masmanidou M, et al. Comparative analysis and effect of GM-CSF on neutropenia in peg-interferon alpha-2b and ribavirin treated chronic hepatitis C patients. Hepatology 2002;36:587.
101. Carey E, Rosati M, Anderson M, et al. Use of G-CSF allows for optimal PEG-INF dosing during therapy for hepatitis C virus with pegylated interferon and ribavirin. Hepatology 2002;36:604.
102. Gronbaek K, Krarup HB, Ring-Larsen H, et al. Interferon alfa-2b alone or combined with recombinant granulocyte-macrophage colony-stimulating factor as treatment of chronic hepatitis C. Scand J Gastroenterol 2002;37:840-4.
103. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: Patients with normal aminotransferases levels. Hepatology 1997;23(Suppl 1):133S-6.
104. Tassopoulos NC. Treatment in patients with normal ALT levels. J Hepatol 1999;31(Suppl 1):193-6.
105. Bacon BR. Treatment of patients with Hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36:S179-84.
106. Mathurin P, Moussalli J, Cadranel J, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine aminotransferase activity. Hepatology 1998;27:868-72.
107. Jamal M, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine aminotransferase levels in the Southwestern United States. Hepatology 1999;30:1307-11.
108. Hui C, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated aminotransferases. J Hepatol 2003;38:511-7.
109. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-4.
110. Cividini A, Rebucci C, Silini E, Mondelli MU. Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? Gastroenterology 2001;121:1526-7.
111. Zeuzem S, Diago M, Gane E, et al. International multicentre randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40KD) (Pegasys) and ribavirin (Copegus). Hepatology 2003;38(Suppl 1):208A.
112. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001;33:321-7.
113. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-14.
114. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8.
115. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.
116. Fattovich G, Giustina G, Degos G, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
117. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation 2002;8:350-5.
118. Shiffman M. Retreatment of HCV non-responders with peginterferon and ribavirin: Results from the lead-in phase of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial. Hepatology 2002;36(Pt 2):295A.
119. Jacobsen I, Russo MW, Brown RS, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers. Gastroenterology 2002;122:A626.
120. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepatitis 2001;8:287-92.
121. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002;74:427-37.
122. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-70.
123. Bortolotti F, Jara P, Diaz C, et al. Posttransfusion and community-acquired hepatitis C in childhood. J Pediat Gastroenterol Nutr 1994;18:279-83.
124. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:E53.
125. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-4.
126. Comanor L, Minor J, Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001;8:139-47.
127. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediat 1998;132(3 Pt 1)527-30.
128. Remis RS. The Prevalence of hepatitis C in Canada. Submitted to Health Canada, 2003.
129. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995;74:212-20.
130. Macias J, Melguizo I, Fernandez-Rivera FJ, et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002;21:775-81.
131. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001;33:562-9.
132. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of co infection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 19936:602-10.
133. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994;87:555-61.
134. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co infection: The Swiss HIV Cohort Study. Lancet 2000;356:1800-5.
135. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. J Am Med Assoc 2002;288:199-206.
136. Klein MB, LaLonde RG, Suissa S. Hepatitis C (HCV) co-infection is preventing the realization of substantial health benefits associated with HAART Abstract 216. In: 11th Annual Canadian Conference on HIV/AIDS Research 2002, Winnipeg, Manitoba.
137. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002;16:1915-23.
138. Torre D, Tambini R, Cadario F, et al. Evolution of co infection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001;33:1579-85.
139. Aceti A, Pasquazzi C, Zechini B. Alanine aminotransferase decrease in HIV-hepatitis C virus co-infected patients responding to antiretroviral therapy. AIDS 2003;17:2141-2.
140. Perronne C, Carrat F, Bani-Sadr F, et al. Final results of ANRS HC02-RIBAVIC: A randomized controlled trial of pegylated-interferon-a-2b plus ribavirin vs. interferon-a-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. Abstract 117LB. In: 11th Conference on Retroviruses and Opportunistic Infections, February 8-11; 2004, San Francisco, MA 2004.
141. Moreno L. Pegylated interferon-alpha 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004;18:67-73.
142. Chung R, Andersen J, Volberding P, et al. A randomized, controlled trial of PEG-interferon-alpha-2a plus ribavirin vs. interferon-a-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons: Follow-up results of ACTG A5071. Abstract 110. In: 11th Conference on Retroviruses and Opportunistic Infections, February 8-11; 2004, San Francisco, MA, 2004.
143. Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al. Final results of APRICOT: A randomized, partially blinded, international trial evaluating peginterferon-a-2a + ribavirin vs. interferon-a-2a + ribavirin in the treatment of HCV in HIV/HCV co-infection. Abstract 112. In: 11th Conference on Retroviruses and Opportunistic Infections, February 8-11; 2004, San Francisco, MA, 2004.
144. Hammoud G, Li J, Vega K, et al. Poor tolerability to high Dose Peg Interferon and Ribavirin in HIV/HCV co-infected patients; initial results from a randomized multicentre trial. Hepatology 2003;38(Suppl 1):327A.
145. Lafeuillade A, Hittinger O, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV co infection. Lancet 2001;357:280-1.
146. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, et al. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1803-4.
147. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1803-4.
148. Sim SM, Hoggard PG, Sales SD, et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: A concentration-dependent interaction. AIDS Res Hum Retroviruses 1998;14:1661-7.
149. Gisolf EH, Dreezen C, Danner SA, et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000;31:1234-9.
150. Van Leth F, Hassink EA, Phanuphak P, et al. Results of the 2NN Study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined together with stavudine and lamivudine. Abstract 176. In: 10th Conference on Retroviruses and Opportunistic Infections, February 2003, Boston, MA, 2003.
151. Fortgang IS, Belitsos PC, Chaisson RE, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
152. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
153. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-8.
154. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35:182-9.
155. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
156. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998;27:1321-2.
157. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-8.
158. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. November 2003.
159. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002;185(Suppl 2):S128-37.